Hingwala Jay, Whitlock Reid, Dunsmore Sara, Armstrong Sean, Tangri Navdeep, Komenda Paul
Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Canada
Health Sciences Center, Winnipeg, Canada.
Perit Dial Int. 2017 Jul-Aug;37(4):481-482. doi: 10.3747/pdi.2016.00282.
Refractory non-malignant ascites is associated with significant morbidity. Serial, large-volume paracentesis is a common treatment. Tunneled peritoneal dialysis (PD) catheters are an effective treatment for refractory malignant ascites, but there are limited data on complications and effectiveness for non-malignant ascites. We reviewed all 13 PD catheter insertions between 2010 - 2015 for this indication at our center. The median catheter survival time was 146 days. No complications occurred during catheter insertion, and no mechanical complications occurred after catheter insertion. One case of peritonitis developed over 217 catheter months. Peritoneal dialysis catheters may be a safe and effective option to manage refractory non-malignant ascites. Prospective, randomized trials are needed to better evaluate potential risks and benefits.
难治性非恶性腹水与显著的发病率相关。连续大量腹腔穿刺术是一种常见的治疗方法。隧道式腹膜透析（PD）导管是治疗难治性恶性腹水的有效方法，但关于非恶性腹水的并发症和有效性的数据有限。我们回顾了2010年至2015年间在我们中心因该适应症进行的13例PD导管插入术。导管中位生存时间为146天。导管插入过程中未发生并发症，插入后也未发生机械性并发症。在217个导管月期间发生了1例腹膜炎。腹膜透析导管可能是管理难治性非恶性腹水的一种安全有效的选择。需要进行前瞻性随机试验以更好地评估潜在风险和益处。
